Amanda Giancarelli1, Kara L Birrer2, Rodrigo F Alban3, Brandon P Hobbs2, Xi Liu-DeRyke4. 1. Department of Pharmacy, Orlando Regional Medical Center, Orlando, Florida. Electronic address: amanda.giancarelli@orlandohealth.com. 2. Department of Pharmacy, Orlando Regional Medical Center, Orlando, Florida. 3. Department of Surgical Education, Orlando Regional Medical Center, Orlando, Florida. 4. Department of Pharmacy, Orlando Regional Medical Center, Orlando, Florida. Electronic address: xi.liu@flhosp.org.
Abstract
BACKGROUND: Massive transfusion protocol (MTP) is increasingly used in civilian trauma resuscitation. Calcium is vital for coagulation, but hypocalcemia commonly occurs during massive transfusion due to citrate and serum calcium chelation. This study was conducted to determine the incidence of hypocalcemia and severe hypocalcemia in trauma patients who receive massive transfusion and to compare characteristics of patients with severe versus nonsevere hypocalcemia. MATERIALS AND METHODS: This was a retrospective study of trauma patients who received massive transfusion between January 2009 and November 2013. The primary outcome was the incidence of hypocalcemia (ionized calcium [iCa] < 1.12 mmol/L) and severe hypocalcemia (iCa < 0.90 mmol/L). Secondary outcomes included calcium monitoring, calcium replacement, and correction of coagulopathy. RESULTS: There were 156 patients included; 152 (97%) experienced hypocalcemia, and 111 (71%) had severe hypocalcemia. Patients were stratified into iCa ≥ 0.90 (n = 45) and iCa < 0.90 (n = 111). There were no differences in demographics or baseline laboratories except the severe hypocalcemia group had higher baseline activated partial thromboplastin time (29.7 [23.7-50.9] versus 25.8 [22.3-35.9], P = 0.003), higher lactic acid (5.8 [4.1-9.8] versus 4.0 [3.1-7.8], P = 0.019), lower platelets (176 [108-237] versus 208 [169-272], P = 0.003), and lower pH (7.14 [6.98-7.28] versus 7.23 [7.14-7.33], P = 0.019). Mortality was higher in the severe hypocalcemia group (49% versus 24%, P = 0.007). Patients in the iCa < 0.90 group received more blood products (34 [23-58] versus 22 [18-30] units, P < 0.001), and calcium chloride (4 [2-7] versus 3 [1-4] g, P = 0.002), but there was no difference in duration of MTP or final iCa. Neither group reached a median iCa > 1.12. CONCLUSIONS: Hypocalcemia is common during MTP, and vigilant monitoring is warranted. Research is needed to effectively manage hypocalcemia during massive transfusion.
BACKGROUND: Massive transfusion protocol (MTP) is increasingly used in civilian trauma resuscitation. Calcium is vital for coagulation, but hypocalcemia commonly occurs during massive transfusion due to citrate and serum calcium chelation. This study was conducted to determine the incidence of hypocalcemia and severe hypocalcemia in traumapatients who receive massive transfusion and to compare characteristics of patients with severe versus nonsevere hypocalcemia. MATERIALS AND METHODS: This was a retrospective study of traumapatients who received massive transfusion between January 2009 and November 2013. The primary outcome was the incidence of hypocalcemia (ionizedcalcium [iCa] < 1.12 mmol/L) and severe hypocalcemia (iCa < 0.90 mmol/L). Secondary outcomes included calcium monitoring, calcium replacement, and correction of coagulopathy. RESULTS: There were 156 patients included; 152 (97%) experienced hypocalcemia, and 111 (71%) had severe hypocalcemia. Patients were stratified into iCa ≥ 0.90 (n = 45) and iCa < 0.90 (n = 111). There were no differences in demographics or baseline laboratories except the severe hypocalcemia group had higher baseline activated partial thromboplastin time (29.7 [23.7-50.9] versus 25.8 [22.3-35.9], P = 0.003), higher lactic acid (5.8 [4.1-9.8] versus 4.0 [3.1-7.8], P = 0.019), lower platelets (176 [108-237] versus 208 [169-272], P = 0.003), and lower pH (7.14 [6.98-7.28] versus 7.23 [7.14-7.33], P = 0.019). Mortality was higher in the severe hypocalcemia group (49% versus 24%, P = 0.007). Patients in the iCa < 0.90 group received more blood products (34 [23-58] versus 22 [18-30] units, P < 0.001), and calcium chloride (4 [2-7] versus 3 [1-4] g, P = 0.002), but there was no difference in duration of MTP or final iCa. Neither group reached a median iCa > 1.12. CONCLUSIONS:Hypocalcemia is common during MTP, and vigilant monitoring is warranted. Research is needed to effectively manage hypocalcemia during massive transfusion.
Authors: Karim Asehnoune; Zsolt Balogh; Giuseppe Citerio; Andre Cap; Timothy Billiar; Nino Stocchetti; Mitchell J Cohen; Paolo Pelosi; Nicola Curry; Christine Gaarder; Russell Gruen; John Holcomb; Beverley J Hunt; Nicole P Juffermans; Mark Maegele; Mark Midwinter; Frederick A Moore; Michael O'Dwyer; Jean-François Pittet; Herbert Schöchl; Martin Schreiber; Philip C Spinella; Simon Stanworth; Robert Winfield; Karim Brohi Journal: Intensive Care Med Date: 2017-07-29 Impact factor: 17.440
Authors: Hunter B Moore; Matthew T Tessmer; Ernest E Moore; Jason L Sperry; Mitchell J Cohen; Michael P Chapman; Anthony E Pusateri; Francis X Guyette; Joshua B Brown; Matthew D Neal; Brian Zuckerbraun; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2020-05 Impact factor: 3.313
Authors: Sharven Taghavi; Sarah Abdullah; Eman Toraih; Jacob Packer; Robert H Drury; Oguz A Z Aras; Emma M Kosowski; Aaron Cotton-Betteridge; Mardeen Karim; Nicholas Bitonti; Farhana Shaheen; Juan Duchesne; Olan Jackson-Weaver Journal: J Trauma Acute Care Surg Date: 2022-03-01 Impact factor: 3.697
Authors: Zachary A Matthay; Alexander T Fields; Brenda Nunez-Garcia; Maya H Patel; Mitchell J Cohen; Rachael A Callcut; Lucy Z Kornblith Journal: J Trauma Acute Care Surg Date: 2020-11 Impact factor: 3.313
Authors: José Luís Alves; João Mendes; Ricardo Leitão; Ana Paula Silva; Anabela Mota Pinto Journal: Eur J Trauma Emerg Surg Date: 2020-08-01 Impact factor: 3.693